Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint

Dario Cattaneo, Sara Baldelli, Simone Castoldi, Nitin Charbe, Valeria Cozzi, Serena Fucile, Emilio Clementi

Research output: Contribution to journalArticlepeer-review


We document our experience with therapeutic drug monitoring (TDM) of antiretroviral agents (1807 determinations) carried out as day-by-day clinical practice for the optimization of drug dosing in HIV-infected patients. A significant proportion of patients had lopinavir, atazanavir and nevirapine trough concentrations exceeding the upper therapeutic threshold. Further studies are needed to identify good candidates/drugs for TDM, eventually allowing the selection of patients who may benefit from TDM-driven adjustments in antiretrovirals dosage.

Original languageEnglish
Pages (from-to)2477-2480
Number of pages4
JournalAIDS (London, England)
Issue number16
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases
  • Medicine(all)


Dive into the research topics of 'Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint'. Together they form a unique fingerprint.

Cite this